

Index

A

Acetylcholine, 130, 133, 138, 142
Addiction, 157–159, 161, 163, 165
Adolescence, 27, 28
Alcohol, 29, 32, 36
Anxiety, 157, 158, 163

B

Bupropion, 127, 130, 131, 137, 141, 145

C

Conditioned stimuli, 65, 72, 76, 78, 82, 85
Contextual conditioning, 76, 77, 86

D

Dopamine, 128, 131, 132, 134, 136, 139,
141–143, 146
Dorsal striatum, 130

E

E-cigarettes, 42
Endocannabinoids, 135
Extracellular, 59, 61, 62, 65, 66, 70–74, 76–81,
83, 84

F

Female, 27

G

GABA, 135, 139, 142
Glutamate, 133, 138, 142, 145

H

Habenulo-interpeduncular circuit, 129

I

Infusion duration, 23, 24
Insula, 130
Interpeduncular nucleus, 112

M

Medial habenula, 112
MHB–IPN, 113
Monoamine oxidase, 31
Mood disorders, 161

N

Nicotine, 157–165
Nicotine replacement therapy, 130
Nicotine withdrawal, 99–101, 103–105,
106–108, 110, 111
Nucleus accumbens, 128
Nucleus accumbens core, 58, 60–62, 66–71,
76–79, 81, 85
Nucleus accumbens shell, 58–62, 64–74, 76,
78–80, 81, 84, 85

O

Operant, 25, 31, 32, 34, 40
Orexin, 141, 144

R

Reinforcement enhancement, 21, 25, 31, 38,
40, 42

S

Schizophrenia, [158–161](#), [165](#)
Self-administration, [21–27](#), [29–35](#), [37–40](#), [43](#),
[44](#)
Smoke constituents, [28](#)
SNP, [99](#), [101](#), [102](#), [114](#), [115](#)
Subunits, [101](#), [102](#), [105](#), [106](#), [108](#)

V

Varenicline, [127](#), [128](#), [130–132](#), [138](#), [142](#), [145](#)
Ventral tegmental area, [128](#)
Visual stimulus, [26](#)